The world’s first inactivated COVID-19 vaccine developed and produced by Sinopharm Group’s China National Biotec Group (CNBG) was approved by the National Food, Drugs and Medical Technology Administration (ANMAT) under the Ministry of Health of Argentina on August 13 for trial test.
China will cooperate with ELEA in Argentina to promote the international clinical trials (phase III) of the above vaccine in Argentina.
At the launching ceremony, representatives of the Argentine government issued a clinical trial approval certificate for the covid-19 inactivated vaccine to Sinopharm Group China Biotech (CNBG).